A detailed history of South Dakota Investment Council transactions in Incyte Corp stock. As of the latest transaction made, South Dakota Investment Council holds 170,735 shares of INCY stock, worth $13.1 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
170,735
Previous 170,735 -0.0%
Holding current value
$13.1 Million
Previous $10.4 Million 9.04%
% of portfolio
0.22%
Previous 0.21%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$51.18 - $63.75 $56,349 - $70,188
-1,101 Reduced 0.64%
170,735 $10.4 Million
Q4 2023

Feb 01, 2024

SELL
$52.16 - $64.19 $271,232 - $333,788
-5,200 Reduced 2.94%
171,836 $10.8 Million
Q3 2023

Nov 07, 2023

SELL
$57.77 - $65.93 $742,228 - $847,068
-12,848 Reduced 6.77%
177,036 $10.2 Million
Q2 2023

Aug 10, 2023

SELL
$60.95 - $75.51 $731,400 - $906,120
-12,000 Reduced 5.94%
189,884 $11.8 Million
Q1 2023

May 10, 2023

BUY
$70.23 - $86.01 $709,323 - $868,701
10,100 Added 5.27%
201,884 $14.6 Million
Q4 2022

Feb 07, 2023

SELL
$67.18 - $84.11 $423,234 - $529,893
-6,300 Reduced 3.18%
191,784 $15.4 Million
Q2 2022

Aug 11, 2022

SELL
$66.18 - $83.18 $14,824 - $18,632
-224 Reduced 0.11%
198,084 $15 Million
Q1 2022

May 10, 2022

SELL
$66.02 - $79.71 $3.25 Million - $3.92 Million
-49,172 Reduced 19.87%
198,308 $15.8 Million
Q4 2021

Feb 08, 2022

BUY
$63.34 - $74.11 $13.8 Million - $16.1 Million
217,580 Added 727.69%
247,480 $18.2 Million
Q3 2021

Nov 09, 2021

BUY
$68.67 - $84.02 $2.05 Million - $2.51 Million
29,900 New
29,900 $2.06 Million
Q3 2020

Nov 06, 2020

SELL
$85.07 - $109.69 $187,153 - $241,318
-2,200 Closed
0 $0
Q1 2020

May 11, 2020

BUY
$63.18 - $85.97 $138,996 - $189,134
2,200 New
2,200 $161,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $17.1B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track South Dakota Investment Council Portfolio

Follow South Dakota Investment Council and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of South Dakota Investment Council, based on Form 13F filings with the SEC.

News

Stay updated on South Dakota Investment Council with notifications on news.